Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Liaison Plex Respiratory Flex Assay

Related Conditions

Often studied with 12 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06392451Not ApplicableUnknown

LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia

NCT02862262Not ApplicableCompleted

A Multi-Site Clinical Evaluation of the ARIES Bordetella Assay in Symptomatic Patients

Showing all 2 trials

Research Network

Common Treatments

  • Liaison Plex Respiratory Flex Assay1
  • Aries Bordetella Assay1
  • Liaison Nes Flu Ab Rsv Covid191

Active Sponsors

  • Luminex Molecular Diagnostics1
  • DiaSorin Molecular LLC1

Top Investigators

Related Conditions

  • Mycoplasma Pneumonia1
  • Influenza Type B1
  • Bordetella Pertussis Infection1
  • Para Influenza1
  • Bordetella Pertussis Infection Respiratory1

Activity Timeline